

**Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes**

Date: November 16, 2023

Chairperson: not yet elected

Erin Halverson, Iowa Medicaid staff, assisted in running the meeting as the last chairperson was not re-appointed to the committee for this term. Elections will take place at the next meeting in April.

Time: 9:30 a.m. to 12:29 p.m.

Location: Grimes State Office Building Room B100, 400 E 14th Street, Des Moines, IA 50319

Committee Members Present: Jason Kessler, M.D.; Jennifer Doudna, Pharm.D., R.Ph.; Lacey Ferguson, Pharm.D.; Rachel Kinn, Pharm.D.; and Jason Kruse, D.O. (Vacancies July 2023: 1 Physician, 1 Physician Assistant)

Iowa DHHS Staff Present: Abby Cate, Pharm.D., Pharmacy Consultant; and Darian Forcier, Pharmacy Administrative Support.

Iowa Medicaid Staff Present: Jacquelyn Hedlund, M.D., MS; Paige Clayton, Pharm.D.; Erin Halverson, R.Ph.; Gina Kuebler, R.Ph.; and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Jordan Thoman, Amerigroup Iowa; Emily Rogers, Iowa Total Care; and Candace Jordan, Molina Healthcare of Iowa.

Erin Halverson called the meeting to order.

- I. Erin Halverson asked that each committee and DHHS/Medicaid staff member introduce themselves to the public. Rachel Kinn made the motion to approve the April minutes, and Jason Kruse seconded. The motion passed with no objections. The committee also approved minor changes to the P&T Committee By-Laws, mainly due to the Department of Human Services merging with the Department of Public Health to form the Department of Health and Human Services (DHHS). Jason Kessler made that motion, Rachel Kinn seconded, and all members were in favor. There were no new verbal conflict of interest disclosures. Forms were provided to the committee members so they could complete their annual disclosures.
- II. Follow-up from Last Meeting: At the April meeting, Dr. Kessler inquired about coverage of Imcivree. It was noted that it currently isn't covered as Iowa's current state plan reflects Iowa Medicaid does not cover drugs for weight loss. A change to this policy would require a state plan amendment and approved funding. It could, however, be considered under exception to policy (ETP). He requested information regarding how many ETPs have been submitted with outcome. Findings had been prepared for the August meeting, which was cancelled, with no additional follow-up since then. However, as of August, none of the FFS or MCO contractors had received any requests.

- III. PDL Revision Notifications (Erin Halverson): The fax blasts sent to providers since the last P&T Meeting in April, to notify them of preferred drug list changes, were reviewed. Due to availability issues for methotrexate injection and albuterol products, Otrexup, Rasuvo, and Albuterol HFA inhalers were made preferred on the PDL.
- IV. Drug Rebate Issues (Dr. Clayton): The AMP cap removal, effective in January 2024, could cause PDL changes due to manufacturers' responses to that change. Currently, it is possible for Medicaid programs to have a negative price for medications once all rebates are received from the manufacturers. There is a provision in the American Rescue Plan Act that removes what is currently a 100% average manufacturer price cap on these products for the federal rebates. As of today, if an inflationary component or best price provision of a federal rebate were to exceed 100% of the manufacturer's average manufacturing price, that is where it would currently be capped. However, within the American Rescue Plan Act beginning January 1, 2024, that would be removed, and the manufacturer would potentially have to pay a state for utilization of a product exceeding that price at which they are producing it. As a result, some manufacturers are making price reductions, while others are removing drugs from the market. Future PDL recommendations will have to take these changes into account, to make cost-effective decisions for the state.
- V. PA Criteria/Pro-DUR Edits (Dr. Cate): There were no updates.
- VI. Legislation (Dr. Cate): There were no updates.
- VII. Iowa Medicaid Updates (Dr. Cate): Point of care testing for influenza and streptococcus A has been implemented for MCO Medicaid members, allowing pharmacists to test for those at pharmacies and also prescribe medications based on test results. Options for members with fee-for-service Medicaid coverage are still being discussed.
- VIII. Public Comment: In addition to the written public comments provided to committee members and posted at <http://www.iowamedicaidpdl.com/public-comments>, they heard oral public comment from the speakers shown below. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

Name	Representing	Drug/Topic
Audrey Montoya	Ascendis Pharma	Skytrofa
Bradley Jones	Abbvie	Ubrelyvy
Ralph Rivera	Pharming Healthcare	Joenja
Lindsay Bebout	Indivior	Opvee
Mark Sullivan	Pierre Fabre Pharmaceuticals	Hemangeol
Sarah Sanders	Novartis	Cosentyx & Kesimpta
Tobie Escher	Intra Cellular Therapies	Caplyta
Timothy Birner	Alkermes	Lybalvi
Nila Stevens	Sanofi	Dupixent & Altuviiio
Eric Aguirre	Astra Zeneca	Fasenra
Corey Hicks	Amgen	Ravicti
Jeffrey Olearczyk	Amgen	Tezspire
Kristi Totten	Azurity Pharmaceuticals	Triptodur

Provider Comments Received:

Altuviio, Skytrofa, Sogroya, Daybue, Long-Acting Growth Hormones, Uzedy (2), Dupixent (2), Triptodur, Hemangeol

Manufacturer Comments Received:

Austedo XR, Sogroya, Altuviio, Opvee, Daybue, Ubrelvy, Vraylar, Tyvaso, Krazati, Ngenla, Uzedy, Lupron Depot Ped, Pheburane, Siklos, Bonjesta, Endari, Xelstrym, Secuado, Rybelsus, Ozempic, Rexulti, Abilify Asimtufii, Konvomep, Adbry, Entyvio

At 10:32, Jason Kessler motioned to go to closed session as authorized by Iowa Code Section 21.5(1)(a) of the Open Meetings Law to review or discuss economic records associated with the PDL which are required or authorized to be kept confidential, and the motion passed with unanimous roll call approval. Open session resumed at 11:45.

IX. PDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 3) were made to maximize cost savings to the program unless otherwise noted.

1. Dulera to Preferred.
2. Qvar RediHaler to Preferred.
3. Arnuity Ellipta to Preferred.
4. Briviact tablets to Preferred.
5. Emend oral suspension to Non-Preferred with Conditions.
6. Nucala Auto-Injector to Preferred with Conditions.
7. Simponi to Preferred with Conditions.
8. Orencia ClickJect to Preferred with Conditions.
9. Xeljanz oral solution to Non-Preferred with Conditions.
10. Invega Hafyera to Preferred Step 2.
11. Vraylar to Preferred Step 2.
12. Trospium chloride to Preferred.
13. Valcyte oral solution to Non-Preferred.
14. Valganciclovir oral solution to Preferred.
15. Zegalogue to Preferred (remove step through reconstitution product).
16. Baqsimi to Preferred (remove step through reconstitution product).
17. Orilissa to Preferred with Conditions.

Jason Kruse motioned to accept the recommendations above, and Jennifer Doudna seconded. The decision was unanimous.

18. Mircera to Non-Preferred with Conditions.
19. Levofloxacin oral solution to Non-Preferred.
20. Febuxostat to Preferred with Conditions.
21. Releuko to Preferred with Conditions.
22. Granix to Preferred with Conditions.
23. Nyvepria to Preferred with Conditions.

24. Fulphila to Non-Preferred with Conditions.
25. Genotropin to Preferred with Conditions.
26. Sodium Polystyrene Sulfonate to Non-Preferred due to risk of adverse events.
27. SPS to Non-Preferred due to risk of adverse events.
28. Aubagio to Non-Preferred with Conditions.
29. Fingolimod to Preferred with Conditions.
30. Gilenya to Non-Preferred with Conditions.
31. Morphine rectal suppositories to Non-Preferred with Conditions.
32. Oxycodone oral concentrate to Non-Preferred with Conditions.
33. Tobramycin and Dexamethasone ophthalmic suspension to Preferred.
34. Quillivant XR to Preferred with Conditions.
35. Qelbree to Preferred with Conditions.
36. Ermeza oral solution to Preferred with prior authorization.

Jennifer Doudna motioned to accept the recommendations above, and Jason Kessler seconded. The decision was unanimous.

- X. RDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 5) were made to maximize cost savings to the program unless otherwise noted.

1. Prezcofix to Preferred.

Rachel Kinn motioned to accept the recommendation above, and Jason Kruse seconded. The decision was unanimous.

- XI. Newly Released Drugs (Dr. Hedlund and Erin Halverson): All following recommendations (with numbering as provided on agenda attachment 6) were made to maximize cost savings to the program unless otherwise noted. Complete new drug monographs can be found on the November meeting page at http://www.iowamedicaidpdl.com/schedule_page/november-16-2023. Dr. Hedlund reviewed the clinical information for the new drugs, and then Erin Halverson read through the recommendations as follows:

1. Altuviiiio- Recommend status on the PDL as Non-Preferred
2. Daybue- Recommend status on the PDL as Non-Preferred
3. Filspari- Recommend status on the PDL as Non-Preferred
4. Inpefa- Recommend status on the PDL as Non-Preferred
5. Jaypirca- Recommend status on the RDL as Non-Recommended with Conditions
6. Joenja- Recommend status on the PDL as Non-Preferred
7. Krazati- Recommend status on the RDL as Non-Recommended with Conditions
8. Miebo- Recommend status on the PDL as Non-Preferred
9. Ngenla- Recommend status on the PDL as Non-Preferred with Conditions
10. Odactra- Recommend status on the PDL as Non-Preferred with Conditions
11. Orserdu- Recommend status on the RDL as Non-Recommended with Conditions
12. Relyvrio- Recommend status on the PDL as Non-Preferred
13. Sogroya- Recommend status on the PDL as Non-Preferred with Conditions
14. Tezspire- Recommend status on the PDL as Non-Preferred with Conditions

- 15. Vanflyta- Recommend status on the RDL as Non-Recommended with Conditions
- 16. Veozah- Recommend status on the PDL as Non-Preferred
- 17. Vowst- Recommend status on the PDL as Non-Preferred
- 18. Zavzpret- Recommend status on the PDL as Non-Preferred with Conditions
- 19. Zoryve- Recommend status on the PDL as Non-Preferred with Conditions

Jason Kruse motioned to accept the recommendations above as amended, and Jennifer Doudna seconded. The decision was unanimous.

- XII. Newly Released Generic Drugs (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Adalimumab fkjp	Non-Preferred with Conditions
Adalimumab adaz	Non-Preferred with Conditions
Baclofen Oral Suspension	Non-Preferred with Conditions
Betaine Anhydrous Oral Powder	Non-Preferred
Bismuth Subcit – Metronidazole- Tetracycline	Non-Preferred
Brimonidine Ophth Sol 0.1%	Non-Preferred
Budesonide Rectal Foam	Non-Preferred
Darunavir	Preferred
Dichlorphenamide	Non-Preferred
Gefitinib	Non-Preferred with Conditions
Lisdexamfetamine	Non-Preferred with Conditions
Methsuximide	Non-Preferred
Saxagliptin	Non-Preferred with Conditions
Saxagliptin-Metformin ER	Non-Preferred with Conditions
Teriflunomide	Preferred with Conditions
Tiotropium Bromide Monohydrate Inhal Cap	Non-Preferred
Topiramate Cap ER Sprinkle	Non-Preferred

Rachel Kinn motioned to accept the recommendations above. Jason Kessler seconded, and all members were in favor.

- XIII. New Drug Dosage Forms/Strengths/Combinations/BioSimilar (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Abilify Asimtufii	Preferred Step 2
Adthyza	Non-Preferred
Airsupra	Non-Preferred
Amjevita	Non-Preferred with Conditions
Atorvaliq Oral Suspension	Non-Preferred with Conditions

Austedo XR	Preferred with Conditions
Cyltezo	Non-Preferred with Conditions
Hadlima	Non-Preferred with Conditions
Hulio	Non-Preferred with Conditions
Hyrimoz	Non-Preferred with Conditions
Idacio	Non-Preferred with Conditions
Iyuzeh	Non-Preferred
Konvomep Oral Suspension	Non-Preferred with Conditions
Liqrev	Non-Preferred with Conditions
Opvee	Non-Preferred
Pradaxa Oral Packet	Non-Preferred with Conditions
Rezvoglar KwikPen	Non-Preferred
Uzedy	Non-Preferred Step 3
Yuflyma	Non-Preferred with Conditions
Yusimry	Non-Preferred with Conditions
Zolpidem 7.5mg Capsule	Non-Preferred with Conditions

Jason Kruse motioned to accept the recommendations above. Jason Kessler and Jennifer Doudna both seconded, and all members were in favor.

A motion was made by Jason Kruse to adjourn the meeting. It was seconded by Rachel Kinn, and all in attendance approved. The meeting adjourned at 12:29 p.m. The next scheduled meeting is tentatively set for April 18, 2024.